5 of Last Week's Biggest Winners

The market had a ho-hum week, with most of the major market averages posting small dips. Let's take a closer look at five of this past week's biggest scorchers:

Company

April 8 Weekly Gain My Watchlist
National Semiconductor (NYSE: NSM  ) $24.04 69% Add
XenoPort (Nasdaq: XNPT  ) $9.31 54% Add
ImmunoGen (Nasdaq: IMGN  ) $12.12 35% Add
Allied Irish Banks (NYSE: AIB  ) $3.90 35% Add
VirnetX (AMEX: VHC  ) $21.25 29% Add

Source: Barron's.

National Semi was the market's hottest stock, soaring 69% after agreeing to be acquired by Texas Instruments (NYSE: TXN  ) . The chipmaker is still trading at a slight discount to the $25-a-share cash price, but that's because the deal isn't likely to close until this year's final quarter.

XenoPort soared after the Food and Drug Administration approved the company's restless leg syndrome treatment. This wasn't a given, especially after earlier Horizant tests showed that it may cause pancreatic cancer in lab rats. GlaxoSmithKline (NYSE: GSK  ) is XenoPort's partner on Horizant, but its success will obviously be a bigger needle mover at the relatively smaller XenoPort.

Shares of ImmunoGen jumped after marketing partner Roche reported that its T-DM1 prevented breast cancer tumor growth better than a rival treatment. The biotech's stock has climbed 53% since being recommended to Rule Breakers newsletter service subscribers less than six months ago.

VirnetX padded its prior week gains after being awarded a new patent for secure communications technology in smartphones. VirnetX is already going after several tech giants, and this only bolsters its case in these potentially lucrative patent-infringement lawsuits.

Allied Irish Banks saw green after Ireland announced its banking nationalization plans. Despite some problematic stress test results, at least the bank is assured of being a key player in Ireland's banking future. The shares still have a long way to go to take out the bank's reverse-adjusted 52-week high of $22.75.  

It was a great week for these five stocks. Now let's see if they're up for an encore.

Which of these five stocks do you think will continue to move higher? Share your thoughts in the comment box below.

ImmunoGen is a Motley Fool Rule Breakers choice. GlaxoSmithKline is a Motley Fool Global Gains recommendation. The Fool owns shares of GlaxoSmithKline and Texas Instruments. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Longtime Fool contributor Rick Munarriz enjoys cheering on winners and whispering words of encouragement to the losers. He does not own shares in any of the companies in this story. He is also part of the Rule Breakers newsletter research team, seeking out tomorrow's ultimate growth stocks a day early. The Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1473396, ~/Articles/ArticleHandler.aspx, 8/29/2014 12:40:40 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement